Catégorie : Essais Cliniques

Short-term effects of cannabis consumption on cognitive performance in medical cannabis patients, Phillip Olla et al., 2019

Short-term effects of cannabis consumption on cognitive performance in medical cannabis patients Phillip Olla, Nicholas Rykulski, Jessica L. Hurtubise, Stephen Bartol, Rachel Foote, Laura Cutler, Kaitlyn Abeare, Nora McVinnie, Alana G. Sabelli, Maurissa Hastings, and Laszlo A. Erdodi Applied Neuropsychology : Adult, 2019, 1-11. Doi : 10.1080/23279095.2019.1681424   ABSTRACT This observational study examined the acute cognitive effects of cannabis. We hypothesized that cognitive performance would be negatively affected by acute cannabis intoxication. Twenty-two medical cannabis patients from Southwestern Ontario completed the study. The majority (n¼13) were male. Mean age was 36.0 years, and mean level of education was 13.7 years. Participants were administered the same brief neurocognitive battery three times during [...]

Lire la suite

Cannabis Use Motivations among Adults Prescribed Opioids for Pain versus Opioid Addiction, Selena N. Clem et al., 2019

Cannabis Use Motivations among Adults Prescribed Opioids for Pain versus Opioid Addiction Selena N. Clem, Teresa L. Bigand, Marian Wilson Pain Management Nursing, 2019, 1-5. Doi : 10.1016/j.pmn.2019.06.009   a b s t r a c t Background : Cannabis has been linked to reduced opioid use, although reasons for cannabis use among adults prescribed opioids are unclear. Aims : The purpose of this study was to determine whether motivations for cannabis use differ between adults prescribed opioids for persistent pain versus those receiving opioids as medication-assisted treatment for opioid use disorder. Design : A cross-sectional survey design was used. Participants : Adults prescribed opioids for persistent pain (n [...]

Lire la suite

Cannabis Use Moderates the Relationship between Pain and Negative Affect in Adults with Opioid Use Disorder, Marian Wilson et al.,

Cannabis Use Moderates the Relationship between Pain and Negative Affect in Adults with Opioid Use Disorder Marian Wilson, Hannah Y. Gogulski, Carrie Cuttler,  Teresa L. Bigand, Oladunni Oluwoye,Celestina Barbosa-Leiker, MaryLee A. Roberts Addictive Behaviors, 2017, 30 p. doi : 10.1016/j.addbeh.2017.10.012   Abstract Introduction : Adults in Medication-Assisted Treatment (MAT) for opioid addiction are at risk for substance use relapse and opioid overdose. They often have high rates of cannabis use and comorbid symptoms of pain, depression, and anxiety. Low levels of self-efficacy (confidence that one can self-manage symptoms) are linked to higher symptom burdens and increased substance use. The effects of cannabis use on symptom management [...]

Lire la suite

Efficacy of Dronabinol for Acute Pain Management in Adults with Traumatic Injury : Study Protocol of A Randomized Controlled Trial, Claire Swartwood et al., 2020

Efficacy of Dronabinol for Acute Pain Management in Adults with Traumatic Injury : Study Protocol of A Randomized Controlled Trial Claire Swartwood, Kristin Salottolo, Robert Madayag, David Bar-Or Brain Sciences, 2020, 10, 161, 1-9. Doi : 10.3390/brainsci10030161   Abstract Delta-9-tetrahydrocannabinol (D9-THC) and other cannabinoids present in cannabis (marijuana) have been shown to affect the normal inhibitory pathways that influence nociception in humans. The potential benefits of cannabinoids as an analgesic are likely greatest in hyperalgesic and inflammatory states, suggesting a role as a therapeutic agent for treating acute pain following injury. Dronabinol is a licensed form of D9-THC. The primary objective of this single center randomized [...]

Lire la suite

Bibliographie : Cannabis et Cannabinoïdes en Neurologie, Docteur Christian SUEUR, GRECC, avril 2020

Bibliographie Cannabis et Cannabinoïdes en Neurologie   Docteur Christian SUEUR, GRECC, avril 2020.     Cannabinoïdes et Sclérose en Plaque, p 4. Cannabinoïdes et Migraines, p 7. Cannabinoïdes et maladies neurodégénératives, p 8. Cannabinoïdes et Maladie de Parkinson, p 10. Cannabinoïdes et Maladie de Huntington, p 11. Cannabinoïdes et Maladie d’Alzheimer, p 12.    

Lire la suite

Cannabinoids : the lows and the highs of chemotherapy-induced nausea and vomiting, Toni Leigh Mortimer et al., 2019

Cannabinoids : the lows and the highs of chemotherapy-induced nausea and vomiting Toni Leigh Mortimer, Tom Mabin & Anna-Mart Engelbrecht Future Oncology, 2019 Doi : 10.2217/fon-2018-0530   Despite remaining one of the most widely abused drugs worldwide, Cannabis sativa exhibits remarkable medicinal properties. The phytocannabinoids, cannabidiol and -9-tetrahydrocannabinol, reduce nausea and vomiting, particularly during chemotherapy. This is attributed to their ability to reduce the release of serotonin from enterochromaffin cells in the small intestine, which would otherwise orchestrate the vomiting reflex. Although there are many preclinical and clinical studies on the effects of -9- tetrahydrocannabinol during nausea and vomiting, little is known about the role [...]

Lire la suite

Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability, Ziva D. Cooper et al., 2018

Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability Ziva D. Cooper, Gillinder Bedi, Divya Ramesh, Rebecca Balter, Sandra D. Comer and Margaret Haney Neuropsychopharmacology, 2018, 0, 1–10 Doi : 10.1038/s41386-018-0011-2   Cannabinoids combined with opioids produce synergistic antinociceptive effects, decreasing the lowest effective antinociceptive opioid dose (i.e., opioid-sparing effects) in laboratory animals. Although pain patients report greater analgesia when cannabis is used with opioids, no placebo-controlled studies have assessed the direct effects of opioids combined with cannabis in humans or the impact of the combination on abuse liability. This double-blind, placebo-controlled, within-subject study determined if cannabis enhances the analgesic effects [...]

Lire la suite

Medical cannibus as an alternative for opioids for chronic pain : A case report, Franklin E. Caldera, 2020

Medical cannibus as an alternative for opioids for chronic pain : A case report Franklin E. Caldera SAGE Open Medical Case Reports, 2020, Volume 8, 1–3 DOI : 10.1177/2050313X20907015   Abstract Opioid medication–related deaths have increased to epidemic proportions in the last decade. This report describes a case of 43-year-old female with a traumatic brain injury who developed chronic pain and opioid dependence. The patient expressed concerns and wanted weaning off opioids. Recent legalization of medical marijuana in Pennsylvania allows us to try it as an alternative to opioids for chronic pain. Medical cannibus has risks associated with administration but is safer than opioids. Our patient [...]

Lire la suite

Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults : a preliminary study, Christine A. Rabinak, 2020

Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults : a preliminary study. Rabinak CA, Blanchette A, Zabik NL, Peters C, Marusak HA, Iadipaolo A, Elrahal F Psychopharmacology (Berl)., 2020, Mar 11. doi : 10.1007/s00213-020-05499-8. Science/Homme: Le THC peut être utile dans le trouble de stress post-traumatique (IACM 30 mars 2020) Lors d’une étude contrôlée par placebo avec 71 participants, composée de 3 groupes (25 témoins sains, 27 adultes exposés à un traumatisme sans trouble de stress post-traumatique et 19 patients souffrant d'un trouble de stress post-traumatique), de faibles doses de THC ont réduit la réactivité liée à la menace dans une certaine [...]

Lire la suite

Endocannabinoids : A Promising Impact for Traumatic Brain Injury, Lesley D. Schurman et al., 2017

Endocannabinoids : A Promising Impact for Traumatic Brain Injury Lesley D. Schurman and Aron H. Lichtman Frontiers in Pharmacology, 2017. doi: 10.3389/fphar.2017.00069   The endogenous cannabinoid (endocannabinoid) system regulates a diverse array of physiological processes and unsurprisingly possesses considerable potential targets for the potential treatment of numerous disease states, including two receptors (i.e., CB1 and CB2 receptors) and enzymes regulating their endogenous ligands N-arachidonoylethanolamine (anandamide) and 2-arachidonyl glycerol (2-AG). Increases in brain levels of endocannabinoids to pathogenic events suggest this system plays a role in compensatory repair mechanisms. Traumatic brain injury (TBI) pathology remains mostly refractory to currently available drugs, perhaps due to its heterogeneous [...]

Lire la suite